Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...
Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...
Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...
Individuals with a history of immune-mediated inflammatory diseases (IMIDs) may have a higher risk for sarcoidosis onset, a Japanese study found.
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
Published in Volume 1 of the journal Immunity & Inflammation on December 18, 2025, the article "Reinventing brain immunity in neurodegeneration ...
A new paper in Rheumatology Advances in Practice indicates that TikTok videos about gout are commonly misleading, inconsistent, or inaccurate. The paper is titled "Gout, TikTok and misleading ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback